remov epacadostat valuat
price month
 close
today news remov epacadostat
base case new tp vs although remov
epacadostat significantli chang dcf remain posit
pipelin next month total revenu vs
previous result remov epacadostat sale catalyst
baricitinib fda panel late april gvhd fgfr readout
think risk/reward head baricitinib fda advisori panel
favor next near-term catalyst
think next catalyst fda panel april
model probabl success us approv peak revenu
panel posit could greater upsid sinc us
revenu estim fairli conserv
think gvhd fgfr readout re-focu
investor oncolog pipelin success although
opportun blockbust level think increment
sale add event expect see data trial
ruxolitinib steroid-resist gvhd base case
posit could read gravita studi line patient
itacitinib larger opportun expect data
fgfr program cholangiocarcinoma program
posit posit read larger bladder cancer indic
valuat metric
number share
suiss seek busi compani cover research report result investor awar
firm may conflict interest could affect object report investor consid report
singl factor make invest decis
price apr rate outperform target price analyst alethia young
profit tax
chang work capit
flow oper
free cash-flow firm
flow invest
cash-flow financ activ
chang net cash/debt
total liabil equiti
share wtd average
price book
roe stated-return
biotechnolog compani develop therapeut
unmet medic need compani market jakafi ruxolitinib
myeloprolif disord develop portfolio
therapeut treatment cancer
sky scenario assum full credit ruxolitinib
itacitinib steroid-resist steroid-na gvhd patient
grey sky scenario jakafi valuat use
sum part scenario pipelin indic expans
consid
 close
lower target price data epacadostat
assum epacadostat sale base case highli impact
valuat new tp vs comment
previou quick take sotp suggest trade rang
think stock trade around pivot trial setback think
investor would assign zero credit epacadostat point although still want
see detail biomark analysi see benefit subpopul
tumor mutat burden rnaseq etc mostli curiou
detail analysi understand learn appli futur
trial think key catalyst includ fda panel baricitinib late
april pipelin readout fgfr gvhd program convers
post data think investor discuss prospect acquir
base busi might provid support stock remain bullish
jakafi commerci outlook note discuss thesi
estim jakafi sale total revenu vs
previous result remov epacadostat sale
think risk/reward upcom baricitinib panel tilt
toward neg investor may cautiou
understand outcom april panel meet next catalyst
upcom fda panel discuss us approv baricitinib
get royalti lilli drug current approv europ
estim royalti peak base peak sale us
question around safeti profil relat thrombocytopenia us
estim probabl success peak royalti peak sale
sale convers investor discuss
look construct get catalyst behind us
valuat think compani like gradual reduc
on-going phase epacadostat program compani current multipl
program phase merck pembrolizumab think expect
indic work low base hazard ratio final
ci reveal today fairli cautiou compani find
biomark strategi better inform studi seem molecul
perform expect estim current associ epacadostat
total compani spend lower sg spend
vs previou estim also lower spend around
compar previou model cost remain
think trial alreadi initi take time slow
beyond whatev happen baricitinib catalyst
pipelin also think compani remain aggress
intern effort could yield program target
interest limit pipelin asset blockbust potenti
epacadostat see variou program could add increment revenu
data expect get top-lin press releas studi
steroid refractori patient gvhd mid-year alreadi includ
base case po success add valuat also
gravita studi steroid nave patient itacitinib estim
base would expect success studi
de-risk program bit well itacitnib add
valuat expect data fgfr program cholangiocarcinoma program
although particular indic rel small ad sale
think also de-risk bladder cancer fgfr program data
much larger opportun
compani mention price
alethia young certifi view express report accur reflect person view subject compani
secur part compens directli indirectli relat specif recommend view express
report
